To the editor

JAMA - Journal of the American Medical Association

Volumn 313, Issue 22, 2015, Pages 2285-

  Robey, R Brooks ^a   Block, Clay A ^a   O'Rourke, Daniel J ^a  

^a VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; MEDICAL DECISION MAKING; MOTIVATION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; SMOKING CESSATION; SMOKING HABIT; FEMALE; MALE; PROCEDURES; TOBACCO USE DISORDER;

BENZAZEPINES; FEMALE; HUMANS; MALE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84930809802     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.4978     Document Type: Letter

References (5)

1. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015; 313(7): 687-694.
2. Edwards SA, Bondy SJ, Callaghan RC, Mann RE. Prevalence of unassisted quit attempts in population-based studies: a systematic review of the literature. Addict Behav. 2014; 39(3): 512-519.
3. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011; 183(12): 1359-1366.
4. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; 5:CD009329.
5. Leaviss J, Sullivan W, Ren S, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? a systematic review and economic evaluation. Health Technol Assess. 2014; 18 (33): 1-120.